Reply to Caldwell et al

Affiliations

¹ Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
² Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
³ Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
⁴ Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
⁵ NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
⁶ Cooper Medical School of Rowan University, Camden, New Jersey, USA.
⁷ Department of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USAand.
⁸ Hardy Diagnostics, Santa Maria, California, USA.

Comment

Michael J Satlin et al. Clin Infect Dis. 2022.

. 2022 Aug 24;75(1):180-181.

doi: 10.1093/cid/ciab1001.

¹ Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
² Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
³ Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
⁴ Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
⁵ NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
⁶ Cooper Medical School of Rowan University, Camden, New Jersey, USA.
⁷ Department of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USAand.
⁸ Hardy Diagnostics, Santa Maria, California, USA.

No abstract available

Comment on

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.
Caldwell L, Bapat A, Drumright LN, Lambourne J, Jimenez-England FG, Aries J, Eccersley L, Hallam S, Montoto S, Oakervee H, Riches J, Agrawal SG. Caldwell L, et al. Clin Infect Dis. 2022 Aug 24;75(1):178-179. doi: 10.1093/cid/ciab1000. Clin Infect Dis. 2022. PMID: 34864924 Free PMC article. No abstract available.

1. Bucaneve G, Micozzi A, Menichetti F, et al. . Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMENA) infection program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-87. - PubMed
1. Cullen M, Steven N, Billingham L, et al. . Simple investigation in neutropenic individuals of the frequency of infection after chemotherapy ± antibiotic in a few tumours (SIGNIFICANT) trial group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-98. - PubMed
1. Gafter-Gvili A, Fraser A, Paul M, et al. . Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 1:CDC004386. - PubMed
1. See I, Freifeld AG, Magill SS.. Causative organisms and associated antimicrobial resistance in healthcare-associated, central line-associated bloodstream infections from oncology settings, 2009-2012. Clin Infect Dis 2016; 62: 1203-9. - PMC - PubMed
1. United States Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-c.... Accessed 11 November 2021.